Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 15, Number 10—October 2009


Community-Associated Methicillin-Resistant Staphylococcus aureus, Iowa, USA

Philip Van De Griend, Loreen A. HerwaldtComments to Author , Bret Alvis, Mary DeMartino, Kristopher Heilmann, Gary Doern, Patricia Winokur, Diana DeSalvo Vonstein, and Daniel Diekema
Author affiliations: The University of Iowa Carver College of Medicine, Iowa City, Iowa, USA (P. Van De Griend, L.A. Herwaldt, B. Alvis, K. Heilmann, G. Doern, P. Winokur, D. Diekema); The University of Iowa Hygienic Lab, Iowa City (M. DeMartino); The University of Iowa College of Public Health, Iowa City (L.A. Herwaldt); The University of Iowa Hospitals and Clinics, Iowa City (L.a. Herwaldt, D. Diekema); The Iowa City Veterans Administration Medical Center, Iowa City (P. Winokur, D.D. Vonstein, D. Diekema)

Main Article

Table 3

Antimicrobial drug susceptibility of 54 invasive MRSA USA300/400 isolates, Iowa, USA, 2006*

Antimicrobial agent % Susceptible
Erythromycin 9
Levofloxacin 57
Clindamycin† 93
Tetracycline 93
Mupirocin 98
Rifampin 98
Trimethoprim/sulfamethoxazole 100
Vancomycin 100
Gentamicin 100
Daptomycin 100
Linezolid 100

*MRSA, methicillin-resistant Staphylococcus aureus.
†Includes D-testing of all erythromycin-resistant, clindamycin-susceptible isolates.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO